Oversight Committee to Hold Hearing With AbbVie CEO and Experts on Pricing Practices for Humira and Imbruvica
May 15, 2021
May 15, 2021
WASHINGTON, May 15 -- Rep. Carolyn Maloney, D-New York, chair of the House Oversight and Reform Committee, issued the following news release on May 14, 2021:
On Tuesday, May 18, 2021, at 10:00 a.m., Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, will hold a hybrid hearing to examine the pricing and business practices of AbbVie Inc., which sells the anti-inflammatory drug Humira and the cancer drug Imbruvica.
Humira is the best-selling . . .
On Tuesday, May 18, 2021, at 10:00 a.m., Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, will hold a hybrid hearing to examine the pricing and business practices of AbbVie Inc., which sells the anti-inflammatory drug Humira and the cancer drug Imbruvica.
Humira is the best-selling . . .